Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO
12:00pm, Monday, 23'rd Feb 2026
LOS ANGELES--(BUSINESS WIRE)--Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO.
Novo Nordisk's Loss Is Eli Lilly's Gain
11:42am, Monday, 23'rd Feb 2026
Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly's tirzepatide, marketed under the Zepbound and Mounjaro bra
Novo Nordisk Tumbles in 'Worst Case Scenario': Next-Gen Weight Loss Drug Underperforms
11:35am, Monday, 23'rd Feb 2026
Novo Nordisk AS (NYSE: NVO), once the darling of the pharmaceutical world, tumbled Monday as investors reacted to what analysts are calling a “worst-case scenario.”
Stock Of The Day: Breakdown In Novo Nordisk?
11:32am, Monday, 23'rd Feb 2026
This means it could keep moving lower, which is why it's our Stock of the Day.
Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why
11:16am, Monday, 23'rd Feb 2026
The weight-loss drug wars took a fresh turn on Monday.
Novo Nordisk Stock Suffers After Weight Loss Drug Underperformance
10:35am, Monday, 23'rd Feb 2026
Novo Nordisk A/S (NYSE:NVO) stock is 14.9% lower to trade at $40.38 at last check, after an 84-week trial showed the pharmaceutical company's next-generation weight loss drug CagriSema wasn't as effe
Why Novo Nordisk Stock Just Crashed
10:31am, Monday, 23'rd Feb 2026
Novo Nordisk just admitted that its CagriSema weight loss drug isn't obviously better than Zepbound. This is a win for Eli Lilly, and a loss for Novo Nordisk.
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
10:21am, Monday, 23'rd Feb 2026
LOS ANGELES--(BUSINESS WIRE)---- $NVO--NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm.
Novo Nordisk CSO on New Obesity Shot Results and Drug Pipeline
10:20am, Monday, 23'rd Feb 2026
Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lill
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
10:01am, Monday, 23'rd Feb 2026
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novo Nordisk: Redefine 4 Misses The Mark
09:54am, Monday, 23'rd Feb 2026
Novo Nordisk shares plunged after CagriSema failed to show non-inferiority to tirzepatide in the pivotal REDEFINE 4 Phase III obesity trial. CagriSema's efficacy lagged, raising uncertainty about Novo
Novo Nordisk's New Weight Loss Shot Loses To Rival Eli Lilly In Clinical Trial—Stock Plummets
09:50am, Monday, 23'rd Feb 2026
Novo Nordisk's experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly's Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo
Novo Nordisk: Why Wegovy Growth Beats Wall Street Expectations
08:30am, Monday, 23'rd Feb 2026
Novo Nordisk shares have fallen 16.4% over the past six months. However, I believe Wall Street is still underestimating the prospects of semaglutide at a dose of 25 mg. Even excluding its approval in
5 Things to Know Before the Stock Market Opens
08:16am, Monday, 23'rd Feb 2026
Stocks are pointing to a lower open amid tariff uncertainty after major indexes posted gains last week; President Donald Trump is imposing new tariffs to replace the ones the Supreme Court struck down
Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value
08:13am, Monday, 23'rd Feb 2026
Novo Nordisk (NYSE:NVO) attempt to reclaim the initiative in the obesity drug race has backfired, after its experimental next-generation treatment failed to prove it was as effective as a rival therap
